Form 4: Guided Therapeutics Director Acquires Shares and Warrants Under Consulting Agreement

Richard P. Blumberg, a director and 10% owner of Guided Therapeutics, acquired shares and warrants as part of a consulting agreement.

Summary

• Richard P. Blumberg, a director and 10% owner of Guided Therapeutics Inc. (GTHP), filed a Form 4 disclosing changes in beneficial ownership.
• On March 1, 2024, Blumberg acquired 400,000 shares of common stock and 900,000 warrants.
• These acquisitions are part of a consulting agreement entered into on March 10, 2021, and subsequently amended.
• Under the agreement, Blumberg provided $350,000 to the company in exchange for 1,600,000 common shares and 3,600,000 warrants with an exercise price of $0.30.
• The issuance of the stock and warrants is contingent on the company obtaining a minimum of $1.0 million in financing and Blumberg's continued service.
• The shares and warrants are to be issued in four equal tranches, with the third tranche issued on March 1, 2024.
• The remaining tranche is due in September 2024.
• Following the reported transaction, Blumberg directly owns 5,965,357 shares of common stock and 2,700,000 warrants.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While insider activity can be positive, the issuance of shares and warrants also dilutes existing shareholders. The consulting agreement provides needed capital, but the company's reliance on it could be a concern.

Positives

• The acquisition of shares and warrants by a director demonstrates confidence in the company.
• The consulting agreement provides the company with $350,000 in funding.
• The staggered issuance of shares and warrants incentivizes continued service from Blumberg.

Risks

• The issuance of shares and warrants could dilute existing shareholders' equity.
• The company's ability to issue the remaining tranche depends on continued financing and Blumberg's service.

Future Outlook

The remaining tranche of shares and warrants is due to be issued in September 2024, contingent on continued financing and Blumberg's service.

Industry Context

This filing reflects insider activity, which is closely monitored by investors for signals about a company's prospects. The consulting agreement suggests the company is leveraging external expertise and capital.

Related Party Transactions

• The consulting agreement with Richard Blumberg is a related party transaction.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• The company benefits from the funding and expertise provided by Blumberg.
• Employees may benefit from the company's improved financial position.

Next Steps

• Issuance of the remaining tranche of shares and warrants in September 2024.
• Continued monitoring of insider transactions.

Key Dates

Keywords

Guided Therapeutics, Richard Blumberg, Form 4, Beneficial Ownership, Shares, Warrants, Consulting Agreement, Financing